Bio-Path Holdings, Inc. announced positive developments in its ongoing clinical trials, including the Phase 1/1b trial of BP1001-A for solid tumors and a Phase 2 study of prexigebersen in Acute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback